| Treatment | Total costs | Total QALYs | ICER |
|---|---|---|---|
| FEV1% utility | |||
| Colistimethate sodium dry powder | £276,593 | 13.00 | - |
| Nebulised tobramycin | £245,561 | 13.04 | Dominant |
| Tinnitus excluded | |||
| Colistimethate sodium dry powder | £276,593 | 11.37 | - |
| Nebulised tobramycin | £206,574 | 11.37 | Dominant |
| Within-trial analysis | |||
| Colistimethate sodium dry powder | £10,563 | 0.42 | - |
| Nebulised tobramycin | £8,417 | 0.42 | Dominant |
| Nebulised tobramycin drug cost | |||
| Colistimethate sodium dry powder | £276,593 | 11.37 | - |
| Nebulised tobramycin | £252,082 | 11.41 | Dominant |
| WinBUGS | |||
| Colistimethate sodium dry powder | £277,013 | 11.36 | |
| Nebulised tobramycin | £245,976 | 11.40 | Dominant |
| PAS | |||
| Colistimethate sodium dry powder | Reduced | 11.37 | - |
| Nebulised tobramycin | Reduced | 11.41 | Increased (>£20,000) |
FEV, forced expiratory volume; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; PAS, patient access scheme; SA, sensitivity analysis
From: Appendix K, Health Economics
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.